BRAF mutation as a biomarker in colorectal cancer

Nearly 10% of colorectal cancers (CRCs) harbor mutations in BRAF . While cytotoxic chemotherapy remains central to the treatment for patients with metastatic CRC, there is a growing understanding that CRC is comprised of molecularly and clinically distinct populations. BRAF -mutant CRC is one such subset. We are learning more about the complexity of BRAF -mutant CRCs and the ways in which patients with BRAF -mutant CRCs may or may not benefit from targeted therapies. This article reviews the role of BRAF as a biomarker in CRC and its implications for treatment.